These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35776182)

  • 1. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.
    Zhu HD; Li X; Ji JS; Huang M; Shao GL; Lu J; Zhao XY; Li HL; Yang ZQ; Tu JF; Zhou JM; Zeng CH; Teng GJ
    Eur Radiol; 2022 Nov; 32(11):7335-7343. PubMed ID: 35776182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
    Sahara S; Kawai N; Sato M; Tanaka T; Ikoma A; Nakata K; Sanda H; Minamiguchi H; Nakai M; Shirai S; Sonomura T
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1363-71. PubMed ID: 22358993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
    Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
    Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Guo W; Chen S; Wu Z; Zhuang W; Yang J
    Technol Cancer Res Treat; 2020; 19():1533033820965587. PubMed ID: 33089769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
    Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
    Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.
    Wei W; Jian PE; Li SH; Guo ZX; Zhang YF; Ling YH; Lin XJ; Xu L; Shi M; Zheng L; Chen MS; Guo RP
    Cancer Commun (Lond); 2018 Oct; 38(1):61. PubMed ID: 30305149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
    Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
    Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
    J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.
    Duan X; Li H; Chen P; Sun T; Kuang D; Lu H; Qiao B; Fan Z; Ren Z; Han X
    Eur Radiol; 2024 Feb; 34(2):1258-1267. PubMed ID: 37581654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
    J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
    Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
    Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
    Zhao C; Yan H; Xiang Z; Wang H; Li M; Huang M
    Invest New Drugs; 2023 Aug; 41(4):617-626. PubMed ID: 37434023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
    Yodono H; Matsuo K; Shinohara A
    Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
    Li T; Zhao J; Zhang S; Wang H; Sun L; Hu J
    J Cancer Res Ther; 2023 Feb; 19(1):57-63. PubMed ID: 37006043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
    Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
    Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.